Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
复制标题
DOI：
10.1016/j.oraloncology.2016.09.010
复制
发表时间：
2017-08
期刊：
影响因子：
4.8
通讯作者：
Uppaluri R
中科院分区：
文献类型：
--
作者：
Zolkind P;Dunn GP;Lin T;Griffith M;Griffith OL;Uppaluri R
最近免疫治疗的成功证明了肿瘤特异性免疫细胞在调节肿瘤排斥反应和产生持久的肿瘤免疫方面的潜力。我们对这些反应的科学基础的理解是更好地理解癌症免疫编辑过程和癌症基因组下一代测序革命的结果。最近的证据表明，T细胞对癌细胞表达的突变蛋白的特异性称为新抗原，是免疫介导的肿瘤排斥反应的重要组成部分。改进的新抗原预测算法使预测和监测对检查点抑制剂和过继转移的自体淋巴细胞的免疫反应成为可能，并使肿瘤特异性治疗性疫苗的开发成为可能。在此，我们综述了免疫疗法中肿瘤新抗原的研究现状及其对未来头颈部癌症治疗的意义。
The recent success of immunotherapies has demonstrated the potency of tumor-specific immune cells in mediating tumor rejection and generating durable tumor immunity. Our understanding of the scientific basis of these responses results from the confluence of a better comprehension of the cancer immunoediting process and the revolution in next generation sequencing of cancer genomes. Recent evidence suggests that T cell specificity for cancer cell expressed mutant proteins – termed neoantigens – is an important component of immune mediated tumor rejection. Improved neoantigen prediction algorithms have made it possible to predict and monitor immune responses to checkpoint inhibitors and adoptively transferred autologous lymphocytes and have enabled the development of tumor-specific therapeutic vaccines. Herein, we review the current research on cancer neoantigens in immunotherapies and its implications for the future of head and neck cancer management.